LadRx Corp (LADXD)

[~ Blue ~]

Up to $343 MILLION in potential milestones for regulatory approvals
and commercial milestones



License with NantCell
, Inc.
?
Exclusive worldwide license for aldoxorubicin in all indications
?
NantCell
plans to initiate multiple trials with aldoxorubicin in
combination with immunotherapy and cell based therapies
?
NantCell
is responsible for future development, manufacturing
and commercialization

?
$13 M up-front as a strategic investment in CytRx at $6.60 per
share split-adjusted, representing a 92% premium to the then current stock price
?
Up to $343 M in potential milestones for regulatory approvals
and commercial milestones
?
Increasing double
-
digit royalties for soft tissue sarcomas
?
Increasing single
-
digit royalties for all other indications

https://cytrxcorporation.gcs-web.com/static-files/bf7ec85c-f083-4a54-a210-2f724edbc531